Loading...
•
Sep 30, 2025
IDEAYA Q3 2025 Earnings Report
IDEAYA reported strong third quarter 2025 financial results, driven by collaboration revenue from a Servier license, resulting in a significant net income turnaround.
Key Takeaways
IDEAYA Biosciences generated substantial collaboration revenue in Q3 2025 from the Servier darovasertib license, leading to a notable net income compared to prior losses and bolstering its cash position to support operations into 2030.
Collaboration revenue of 207834000 in Q3 2025 drove a strong financial performance. :contentReference[oaicite:0]{index=0}
Net income was 119244000, a major turnaround from prior losses. :contentReference[oaicite:1]{index=1}
Basic EPS was 1.35 for the quarter. :contentReference[oaicite:2]{index=2}
Cash, cash equivalents, and marketable securities reached ~1140000000 by quarter-end. :contentReference[oaicite:3]{index=3}
Revenue by Segment
Forward Guidance
IDEAYA highlighted progress on clinical milestones, including anticipated data readouts and IND advancements, supported by its strengthened balance sheet.
Positive Outlook
- Anticipated median PFS data for darovasertib Phase 2/3 trial expected year-end 2025 to Q1 2026. :contentReference[oaicite:4]{index=4}
- Progress on multiple IND filings including IDE892 and IDE034 during Q3 2025. :contentReference[oaicite:5]{index=5}
- Partnership with Servier extending potential commercialization opportunities outside the U.S. and strengthening cash runway. :contentReference[oaicite:6]{index=6}
- Robust cash position expected to fund operations into 2030. :contentReference[oaicite:7]{index=7}
- Pipeline momentum with clinical data presented at major conferences. :contentReference[oaicite:8]{index=8}
Challenges Ahead
- Research and development expenses increased reflecting clinical progression costs. :contentReference[oaicite:9]{index=9}
- Dependence on timing of clinical trial readouts for future catalysts. :contentReference[oaicite:10]{index=10}
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...